Healthcare / Medical Care FacilitiesTokyo
$905.00
+51.00 (+5.97%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 35% · confianza 10%
FCF escenarios
weak_data · normalized FCF $-19.7M · quality 13.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
6/100
F
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.4B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-94.1%
↓Gross Margin
59.4%
↑Debt/Equity
6.57
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-3.6%
FCF CAGR
—
FCF margin
4.4%
FCF / Net income
-0.42x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.87B · net income $-301.0M · FCF $127.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.87B | $2.87B | $3.43B | $2.84B | $3.20B |
| Net Income | $-301.0M | $-301.0M | $104.1M | $-774.5M | $72.4M |
| EBITDA | $-72.2M | $-72.2M | $302.3M | $-620.1M | $329.9M |
| EPS | -202.46 | -202.46 | 71.17 | -552.13 | 50.55 |
| Gross Margin | 59.4% | 59.4% | 54.8% | 43.2% | 51.0% |
| Operating Margin | -5.4% | -5.4% | 3.4% | -17.9% | 4.9% |
| Net Margin | -10.5% | -10.5% | 3.0% | -27.3% | 2.3% |
| Balance Sheet | |||||
| Debt/Equity | 6.57 | 6.57 | 3.95 | 6.40 | 1.32 |
| Current Ratio | 1.25 | 1.25 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $127.0M | $127.0M | $-19.7M | $-467.7M | $-215.6M |
| Returns | |||||
| ROE | -94.1% | -94.1% | 17.2% | -219.3% | 6.3% |
| Valuation | |||||
| P/E | — | — | 28.61 | — | 52.82 |
| EV/EBITDA | — | — | 13.37 | — | 11.97 |
| P/B | 4.21 | 4.21 | 4.92 | 6.15 | 3.34 |
| Growth & Yield | |||||
| Revenue Growth | -16.3% | -16.3% | 20.9% | -11.4% | — |
| EPS Growth | -384.5% | -384.5% | 112.9% | -1192.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-11.4%
Start / end P/E
n/dx → n/dx
EPS bridge
71.17 → -202.46
Residual
-11.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.